Compare AU
Compare VNGS vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vaughan Nelson Global Smid Fund (Managed Fund) (VNGS) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VNGS | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 63 |
Median incremental investment | $0 | $967.00 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,875.72 |
Average age group | N/A | 26 - 35 |
Key Summary
VNGS | DRUG | |
|---|---|---|
Strategy | VNGS.AX was created on 2022-06-01 by Vaughan. The fund's investment portfolio concentrates primarily on extended market equity. The Fund aims to outperform the MSCI ACWI SMID Cap Index (after fees and expenses and before taxes) on a rolling five-year basis. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Monolithic Power Systems Inc (3.37 %) Element Solutions Inc (3.09 %) Cushman & Wakefield PLC (2.66 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (21.22 %) Information Technology (19.22 %) Financials (15.49 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (58.61 %) United Kingdom of Great Britain and Northern Ireland (11.67 %) Japan (4.24 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 1.12 % | 0.57 % |
Key Summary
VNGS | DRUG | |
|---|---|---|
Issuer | Vaughan | BetaShares |
Tracking index | MSCI ACWI SMID Cap Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 1.12 % | 0.57 % |
Price | $3.28 | $8.12 |
Size | $29.266 million | $191.120 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | - % | 1.90 % |
Market | ASX | ASX |
First listed date | 31/05/2022 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VNGS | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 63 |
Median incremental investment | $0 | $967.00 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,875.72 |
Average age group | N/A | 26 - 35 |
Pros and Cons
VNGS | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VNGS | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |